Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Feb 2022 Status changed from not yet recruiting to recruiting, as per Results published in the Journal of Medical Virology
- 01 Feb 2022 Results (n=68)published in the Journal of Medical Virology
- 04 Aug 2020 New trial record